Compare Direxion Daily S&P 500 Bull 3X Shares (SPXL) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily S&P 500 Bull 3X Shares vs Zimmer Biomet Holdings Inc — how do they compare? Direxion Daily S&P 500 Bull 3X Shares trades at $297.5 (market cap $7.36B), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.3× Direxion Daily S&P 500 Bull 3X Shares's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Direxion Daily S&P 500 Bull 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily S&P 500 Bull 3X Shares for 32 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| SPXL | ZBH | |
|---|---|---|
Market Cap | $7.36B | $16.95B |
Volume | 1,835,467 | 2,505,240 |
Sector | Leveraged / Inverse | Health |
52-Week High | $301.38 | $103.98 |
52-Week Low | $170.20 | $79.58 |
Typical Hold Time | 32 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPXL trades at $298.10, up 0.42% with a bullish technical signal from moving averages. The ETF shows neutral momentum oscillators with RSI at 66.91 suggesting mild overbought conditions. Recent news highlights S&P 500 valuation concerns despite strong earnings growth projections of 35% for 2026. The index faces concentration risks with top holdings accounting for 40% of value.
Outlook remains cautiously optimistic with seasonal patterns favoring year-end rallies, though profit growth is expected to slow to 15% in 2027. Key risks include market concentration, geopolitical uncertainty, and potential Fed policy impacts. Technical support at $289 and resistance at $300 will be critical near-term levels.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
